BH3 profiling as pharmacodynamic biomarker for the activity of BH3 mimetics
Rongqing Aaron Pan,
Youzhen Wang,
Shumei Qiu,
Mariana Villalobos-Ortiz,
Jeremy Ryan,
Erick Morris,
Ensar Halilovic,
Anthony Letai
Affiliations
Rongqing Aaron Pan
Bone Marrow Transplantation Center of the First Affiliated Hospital and Institute of Hematology and Department of Immunology, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, China; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215
Youzhen Wang
Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA 02139
Shumei Qiu
Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA 02139
Mariana Villalobos-Ortiz
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA ; Harvard Medical School, Boston, MA 02215
Jeremy Ryan
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA ; Harvard Medical School, Boston, MA 02215
Erick Morris
Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA 02139
Ensar Halilovic
Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA 02139
Anthony Letai
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA ; Harvard Medical School, Boston, MA 02215
